Sakar Healthcare Q1 Results: Net Profit Surges 120% as Oncology Pivot Gains Momentum
Sakar Healthcare delivered a robust performance in Q1 FY27, marked by a 120% jump in net profit and a significant expansion of its specialized oncology segment. The company is successfully transitioning toward a vertically integrated, export-led oncology model with improving operational margins.
Gland Pharma Launches USFDA Approved Sugammadex Injection in 1.6 Billion Dollar US Market
Gland Pharma Limited has secured USFDA approval and executed the market launch of Sugammadex Injection in the United States. This generic alternative to Bridion targets a substantial perioperative therapy segment that recorded $1.6 billion in annual sales through April 2026.
Jeena Sikho Lifecare Launches New Ayurvedic Pain Relief Patches to Expand Wellness Portfolio
Jeena Sikho Lifecare Limited has expanded its domestic product portfolio through the launch of four specialized Ayurvedic pain relief patches. These new offerings target the external application segment, focusing on localized pain management for the back and knees.
RPG Life Sciences Launches Naprosyn ES; First-of-its-Kind Combo in India
RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES, a fixed-dose combination of Naproxen and Esomeprazole, in the Indian market. This product marks the first time this specific anti-inflammatory and gastro-protective combination is available in India, targeting patients requiring long-term pain management.
Granules India Secures Sole First-to-File Status for Sodium Oxybate Generic in US
Granules India has achieved Sole First-to-File status for its Sodium Oxybate Extended-Release ANDA, a generic equivalent of LUMRYZ. This regulatory milestone provides a strategic advantage in the US complex generics market and potentially grants the company marketing exclusivity.
Zydus Lifesciences and Apollo Hospitals Partner to Launch Shield Multi-Cancer Detection Test
Zydus Lifesciences has entered into a Memorandum of Understanding with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test in India. This partnership utilizes Zydus's exclusive agreement with Guardant Health to provide a non-invasive, blood-based screening tool for 10 common cancer types.
Glenmark Pharmaceuticals Advances Phase 3 Trial for Trastuzumab rezetecan in Ovarian Cancer
Glenmark Specialty S.A. has advanced its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate. India marks the initial site for patient enrollment following DCGI approval, with further expansion planned for Australia and South Korea.
Zota Health Care Adds 264 Davaindia Stores in Q1FY27, Network Reaches 2,825 Outlets
Zota Health Care Limited significantly expanded its retail footprint by opening 264 new Davaindia stores during the first quarter of FY27. This growth phase brings the company's total operative store count to 2,825, strengthening its position in the generic medicine retail market.
Shilpa Medicare Commissions Integrated ADC Drug Facility; Net Profit Surges 642%
Shilpa Biologicals Limited, a subsidiary of Shilpa Medicare, has commissioned a specialized Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad, India. This facility integrates payload synthesis and biologic purification, enabling the company to serve as a comprehensive CDMO partner for global oncology innovators.